HomeBUSINESS
BUSINESS

Pfizer Submits New Drug Application in Japan for Dacomitinib
(May.29.2018)

Pfizer Japan announced on May 28 that it has submitted a new drug application in Japan for dacomitinib, an irreversible pan-human EGFR tyrosine kinase inhibitor, for the treatment of patients with EGFR mutation-positive inoperable or relapsed non-small-cell lung cancer (NSCLC) ...
(LOG IN FOR FULL STORY)

News Calendar